In the PACIFIC trial, durvalumab following chemoradiotherapy significantly improved survival in patients with unresectable ...
Morning Overview on MSN
An FDA-approved drug added five months of survival in tough breast cancer
Patients diagnosed with metastatic triple-negative breast cancer, one of the most aggressive and treatment-resistant forms of ...
A novel vaccination strategy against certain malignant brain tumors could fundamentally improve treatment for patients.
A real-world analysis investigates the impact of concurrent GLP-1 RA use on long-term survival and the safety profile of patients with solid and hematologic malignancies receiving immune checkpoint ...
Discover 5 top Big Pharma stocks amid rising cancer, type 2 diabetes and IMIDs—dividend yields, earnings beats and why they ...
The centerpiece of the acquisition is Myricx Bio’s novel N-myristoyltransferase inhibitor payload platform, which could help Novartis develop antibody-drug conjugates that can overcome the limitations ...
The Phase I/II China-based trial will test the combination in patients with PD-L1-positive, EGFR mutated tumors.
Treos Bio, a clinical-stage biotechnology company developing off-the-shelf and personalized active cancer immunotherapies based on its proprietary PEPI Technology, today announced new translational ...
AURORA targets a high-unmet-need population: metastatic non-squamous NSCLC with progression on pembrolizumab and platinum ...
Digestive system cancers, including hepatobiliary and gastrointestinal malignancies, remain a major global oncological burden ...
Immune checkpoint inhibitors like anti-PD-1 have transformed melanoma treatment, yet more than half of patients fail to ...
Phase 3 clinical trial will evaluate aglatimagene besadenovec plus valacyclovir in combination with continued pembrolizumab versus standard-of-care docetaxel chemotherapy in patie ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results